CatalystMarker
← board

QDEL

distress 0/10 · well-funded / low risk
$16.670%today-53% from 52w high
quidelortho.com6,500 employeesFounded 1979San Diego, CAMedical Devices
Revenue
$620M
Liquidity
$140M
Runway
Shares 1y
+0%

Price & events

-45.5% over 6M
$9.96$20.26$30.56Jan 26Apr 26Jul 2614.1Mrating: Citigroup: Neutral (2026-07-08)rating: JP Morgan: Underweight (2026-07-01)rating: Jefferies: Buy → Hold (2026-05-07)rating: Citigroup: Neutral (2026-05-06)rating: UBS: Neutral (2026-04-10)rating: Citigroup: Neutral (2026-02-12)
CatalystRating changeDilutionFinancingdashed = today
-0.1%
1D
-8.6%
1W
+39.6%
1M
+48.3%
3M
-40.7%
6M
-37.3%
1Y
-54.9%
2Y
-88.9%
5Y
-91.2%
All

Overview

Market Cap
$1.14B
Enterprise Value
$3.69B
Volume
51.68K
52 Week Range
$9.96 – $35.38
Total Shares
68.19M
Float Shares
62.11M
Short %
23.05%
% Held by Insiders
0.90%
% Held by Institutions
128.13%
RVOL
0.03x
Beta
0.69

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 3

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 68,190,989 · 0 offerings/1y · 0 PIPEs
  • 2025-08-218-Kmaterial_agreement
  • 2024-12-06SC 13G/Astrategic_stake
  • 2024-11-21SC 13D/Astrategic_stake
  • 2024-11-20424B3offering
  • 2024-11-19S-3ASRshelf_registration
  • 2024-11-19FWPoffering
  • 2024-11-14SC 13G/Astrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

hold · target $21 (+23% upside) · 4 analysts
  • 2026-07-08CitigroupNeutral
  • 2026-07-01JP MorganUnderweight
  • 2026-05-07JefferiesBuy → Hold
  • 2026-05-06CitigroupNeutral
  • 2026-04-10UBSNeutral
  • 2026-02-12CitigroupNeutral

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.